A new acid buffering gel (BufferGel, ReProtect, Inc., Baltimore, Md.) that is supposed to be used with a diaphragm can provide safe, effective contraception.
A new acid buffering gel (BufferGel, ReProtect, Inc., Baltimore, Md.) that is supposed to be used with a diaphragm can provide safe, effective contraception. It may also help protect against sexually transmitted diseases (STDs) caused by acid-sensitive pathogens, including herpes simplex virus, chlamydia, gonorrhea, papillomavirus, and HIV-infected leukocytes, according to an 11-center, randomized, double-masked, noninferiority trial.
Researchers compared 621 women who used the new nondetergent spermicide plus diaphragm with 300 women who used nonoxynol-9 spermicide plus diaphragm for 6 months. The mean age of the participants was 25 years. In a double-masked study extension, the authors of the study followed 234 of the women for an additional 6 months.
They found pregnancy rates, as well as rates of adverse events, changes in vaginal microflora, and acceptability, to be similar between the groups. The 6-month pregnancy rate per hundred women was 10.1% (95% CI, 7.1%–13.1%) for users of the new gel versus 12.3% (95% CI, 7.7%–16.9%) for the nonoxynol-9 users. Six-month rates for those who used the products consistently and correctly were 4.7% for users of the acid gel and 6.1% for the nonoxynol-9 users.
Barnhart KT, Rosenberg MJ, MacKay HT, et al. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm. Obstet Gynecol. 2007;110:577-586.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More